English | 简体中文 | 繁體中文 | 한국어 | 日本語
2021年12月3日 15時00分 JST
Share:
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
- Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily
- PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant
- Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally
- One of the few companies in Singapore with proprietary technology in testing

SINGAPORE, 2021年12月3日 - (JCN Newswire) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.

Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, "As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.

With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."

In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.

The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.

This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.

Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.

About Acumen Diagnostics Pte. Ltd.

Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.

Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more information, please visit the company website at www.acumen-research.com.

For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008, query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg

トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Pixis (Formerly Pyxis One) Raises $100M in SoftBank Vision Fund 2-led Series C to Grow Its Codeless AI Infrastructure 
Jan 22, 2022 02:00 HKT/SGT
2022's First SPAC and Metaverse Investment Opportunities Virtual Investment Conference in Hong Kong 
Jan 21, 2022 20:50 HKT/SGT
Pixis(旧Pyxis One)、コードレスAI基盤の成長を目指し、SoftBank Vision Fund 2が主導するシリーズC資金1億ドルを確保 
Jan 21, 2022 16:00 HKT/SGT
Pixis(旧Pyxis One)、コードレスAI基盤の成長を目指し、SoftBank Vision Fund 2が主導するシリーズC資金1億ドルを確保 
Jan 21, 2022 16:00 HKT/SGT
2022年のTRONについて知っておくべきこと 
Jan 21, 2022 13:00 HKT/SGT
Ingerson Capital Partners Releases the Performance Report on 'Asia Driving Demand for Longer Trading Hours' 
Jan 21, 2022 13:00 HKT/SGT
NECファシリティーズ 産業廃棄物処理施設向け国内初となるホウ素排水処理技術を開発 
Jan 21, 2022 10:00 HKT/SGT
日立がサウジアラビア リヤドのプリンセス・ヌーラ大学と自動運転メトロシステムの運用・保守契約を締結 
Jan 21, 2022 09:00 HKT/SGT
エーザイ、「世界で最も持続可能な100社」に6回目の選定 
Jan 21, 2022 09:00 HKT/SGT
Realbox launches one of the world's first blockchain-based real estate tokenization platforms 
Jan 20, 2022 20:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575